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HLA extended haplotypes in steroid-sensitive nephrotic syndrome of
childhood. Idiopathic nephrotic syndrome has been postulated to have
an immunopathogenic basis. To determine whether steroid-sensitive
nephrotic syndrome is associated with greater than expected frequen-
cies of specific extended haplotypes of the major histocompatibility
complex, we studied genetic markers (Class I, II, III HLA alleles and
glyoxalase I) in 173 subjects in 42 families of patients with nephrotic
syndrome of childhood. The single allele, DQW2, was found in 72% of
steroid sensitive patients compared with only 35% of the controls (P =
0.003). In half of 32 steroid sensitive, but not 10 steroid resistant,
patients, one or both of two specific extended haplotypes (alleles that
segregate together) were identified. The first, [HLA-A I, B8, DR3,
DRW52, SCOI], occurred in 11 of 64 haplotypes, or 17%, compared to
5% of controls (P = 0.017). The other, [HLA-B44, DR7, DRW53,
FC31J, occurred in 10 of 64 haplotypes, 16% compared to 3.8% of
controls (P = 0.014). Five patients had both haplotypes. Patients with
these specific extended haplotypes had a greater frequency of relapses
than did those with other haplotypes. These data provide additional
support for the hypothesis that steroid-sensitive nephrotic syndrome
has an immunogenetic basis.
The etiology of idiopathic nephrotic syndrome of childhood
(minimal change disease) remains unknown. It has become
apparent, however, that there may be an inherited predisposi-
tion for the disease. A European survey which excluded cases
of congenital nephrotic syndrome found that 63 of 1877 ne-
phrotic children had affected family members [1]. This inci-
dence was higher than that predicted from the frequency with
which minimal change nephrotic syndrome occurs. Additional
familial cases, including the occurrence of minimal change
disease in monozygotic twins, have been reported from other
centers [2, 3].
Several abnormalities in both humoral and cellular immune
responses have been described in minimal change disease [4].
These include functional alterations of B cells, T cells, and
macrophages, altered levels of immunoglobulins and lympho-
kines, association with atopy, abnormalities of the complement
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system, susceptibility to pneumococcal infection, and remis-
sion induced by measles, steroids, and cyclophosphamide.
Further evidence of an immunogenetic mechanism for the
disease is the association between nephrotic syndrome and
specific HLA antigens. The human major histocompatibility
complex is located on the short arm of chromosome 6 and
includes three classes of genes, Class I (HLA-A, B, C), Class II
(HLA-DR, DP, DQ), and the Class III genes which control the
synthesis of the complement components C2, Factor B, and C4.
Class III genes located between HLA-B and HLA-DR are
inherited as a unit called a "complotype" [5],and are given in
arbitrary order as Bf, C2, C4A, and C4B alleles. Glyoxalase I
(GLO) is a protein coded by a genetic locus that is also located
on the short arm of chromosome 6 centromeric to the Class II
region. Phenotypic studies of patients with idiopathic nephrotic
syndrome have shown associations of the disorder with a
variety of single HLA antigens including B8 [6—8], B44 [7, 9],
DR3 [10], DR7 [10—13], BfF [14], and C4A*QO [15]. Linkage
disequilibrium (non-random chromosomal association) among
alleles of HLA-A, B, DR, and complotypes produces an asso-
ciation of alleles called an "extended haplotype" [16]. An
association has been observed between susceptibility to specific
diseases and specific extended haplotypes of the major histo-
compatibility complex. For example, the extended haplotype
[HLA-B8, DR3, SCO1] with GLO2 is increased in type I
diabetes mellitus [17], membranoproliferative glomerulone-
phritides types I and III [18] and gluten-sensitive enteropathy
[19].
To determine whether idiopathic nephrotic syndrome might
be associated with specific extended haplotypes, we studied 32
families of patients with steroid-sensitive nephrotic syndrome
and 10 families of patients with steroid-resistant nephrotic
syndrome. Venous blood samples were obtained from the
participants for determination of HLA-A, B, DQ, and DR
antigens as well as for Factor B, C2, C4, and glyoxalase
allotyping. Genotypic analysis allowed us to identify 346 hap-
lotypes. Our findings of an increased frequency of one or both
of two specific extended haplotypes in patients with steroid-
sensitive nephrotic syndrome, compared to the normal popula-
tion, suggest an inherited susceptibility to the disorder for
which these extended haplotypes provide a marker.
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Methods
Subjects
The charts of all Caucasian patients who presented with
nephrotic syndrome in childhood [201 and had been referred to
our center were reviewed. All patients who had nephrotic
syndrome secondary to diseases such as systemic lupus erythe-
matosus, membranoproliferative glomerulonephritis, membra-
nous glomerulonephritis, acute glomerulonephritis, IgA neph-
ropathy, and Alport's disease were excluded from the study.
The remaining patients were categorized as being either steroid
sensitive or steroid resistant using standard criteria [20]. "Ste-
roid sensitive" patients were those with cessation of qualitative
proteinuria for seven consecutive days after a maximum of
eight weeks of treatment with prednisone 2 mg/kg/day in a
single daily dose [20]. Only patients who had been followed by
us for at least one year, and whose families lived within a 200
mile radius of St. Louis were considered for the study, and
steroid sensitive patients must have had at least two relapses of
their nephrotic syndrome and remained steroid responsive to
qualify for the study. The families of all the patients who
fuffilled these criteria were informed of the nature of the study
and asked if they were willing to participate. A total of 42
families agreed to be studied.
The 42 patients had been followed in our clinic for an average
of 7.7 (range 1 to 20) years. In 32 patients, 18 of whom were
male and 14 female, the nephrotic syndrome was steroid
sensitive. The average age of onset of disease was 4.2 (range 0.8
to 11.0) years. Each of the patients had subsequent relapses,
but all remained steroid responsive. The number of relapses
experienced by individual patients ranged from two to live per
year. In every patient, renal function remained normal through-
out the period of observation. Twenty-six of these 32 steroid-
sensitive patients underwent renal biopsy during the course of
their illness; the indications for biopsy included an atypical age
of presentation (older than 6 years or younger than 1 year),
frequent relapses (more than 4 relapses per year), and histologic
determination prior to initiation of cytotoxic therapy. Seven-
teen of the patients had minimal histologic abnormalities, five
had mild mesangial hypercellularity, one had normal light
microscopy but 1gM deposits on immunofluorescence, and
three had a minority of glomeruli with focal changes of segmen-
tal sclerosis. The six patients in this group who did not have a
histologic diagnosis fulfilled all the clinical criteria for minimal
change nephrotic syndrome of childhood [20].
In the 10 steroid resistant patients, of whom four were male,
the mean age of onset of disease was 5.5 (range 1 to 11) years.
All underwent renal biopsy; eight had microscopic changes
consistent with focal segmental glomerulosclerosis, one had
minimal histologic findings, and one had non-specific immune
complex glomerulonephritis. Seven of these patients had pro-
gressed to chronic renal failure. The other three had normal
glomerular filtration rates measured by inulin clearance at the
time of the study.
The 173 individuals in the 42 families that were studied
included most of the natural parents of each patient and all
available siblings. Blood samples were obtained from these
individuals for HLA typing, complotyping, and lyoxalase
determination. We obtained complete haplotypes in every
subject and constructed family pedigrees.
Controls
Data on the frequencies of Class I and II antigens in the North
American Caucasian population was obtained from the report
of the VIII International Histocompatibility Workshop [21].
Frequencies of the DQ alleles, previously called "MB", were
also taken from this report [22]. Complotype [23] and extended
haplotype [161 frequencies were compared with results from
studies of Caucasian families (involving normal chromosomes)
undertaken by Alper and colleagues in Boston [16, 23].
To ensure that our study population was derived from the
same genetic pool as these control populations, we analyzed the
haplotypes which occurred in the family members of our
patients but which were not present in the patients. These have
been referred to as "non-disease associated haplotypes" [17,
18]. Haplotypes that occurred in more than one person in a
family were counted only once unless they were present in an
unrelated person, such as a spouse. There were 81 non-disease
associated haplotypes. The frequencies of Class I and II anti-
gens, of complotypes, and of the extended haplotypes in this
population did not differ from those in the published control
populations [16, 21—23].
Antisera and reagents
Sheep antisera to human complement proteins C4, C2, and Bf
were obtained from ICN Immunobiologicals (Lisle, Illinois,
USA).
HLA typing
HLA-A, B, DQ, and DR antigens were determined by the
HLA laboratory at Washington University (St. Louis, Mis-
souri, USA) by means of the lymphocyte cytotoxicity technique
[24].
Glyoxalase allozyping
Cellulose acetate electrophoresis of erythrocyte lysates was
utilized as described elsewhere [25].
Factor B allotyping
Agarose electrophoresis of EDTA plasma samples was fol-
lowed by immunofixation with goat antihuman factor B. Allo-
types were assigned according to accepted nomenclature [26].
C2 allotyping
C2 allotypes were assigned using one or both of two methods.
EDTA-plasma samples were subjected to isoelectric focusing in
polyacrylamide followed by a C2-specific hemolytic overlay
[27]. The alternative method involved pretreating the EDTA-
plasma samples with neuraminidase Type VI (Sigma, St. Louis,
Missouri, USA) prior to isoelectric focusing, followed by im-
munofixation with sheep antihuman C2 [28].
C4 allotyping
Neuraminidase-treated [29] plasma samples were subjected
to agarose electrophoresis followed by immunofixation with
sheep antihuman C4. Half-null C4 allotypes were identified by a
combination of procedures: family studies, visual inspection,
densitometer tracings of protein patterns, or crossed immuno-
electrophoresis.
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Table 1. The frequencies of Class I, II, and III HLA antigens and of
complotypes in patients with steroid-sensitive nephrotic syndrome





Allele Patients associated Caucasiansa
Classes I and II
B8 13/64(0.20) 9/81(0.11) 0.09
B44 15/64(0.23) 13/81(0.16) 0.14
B13 5/64(0.08) 1/81(0.01) 0.02
DR2 1/64(002)b 6/81(0.07) 0.13
DR3 14/64(0.22) 11/81(0.14) 0,12
DR7 20/64(0.3l)c 8/81(0.10) 0.12
DQW2 23/32(072)d 0.35
Class 111
C4AO 17/64(0.27) 11/80(0.14) 0.19
C4BO 6/64(0.09) 15/80(0.19) 0.10
Bf S 43/64(0.67) 59/80(0.74) 0.80
Bf F 21/64(0.33) 18/80(0.23) 0.17
C2 C 64/64(1.00) 80/80(1.00) 0.96
Complotype
SCO1 13/64(0.20) 8/80(0.10) 0.12
FC3I 12/64(0.19) 13/80(0.16) 0.11
Abbreviation is: RR, relative risk.
a Normal population data from Refs. 21 and 22. There were no
significant differences between these values and the non-disease asso-
ciated haplotypes.b Patients vs. non-disease relatives, P < 0.029, RR 0.19
Patients vs. non-disease relatives, P < 0.002, RR 4.1d Patients vs. Caucasian controls, P <0.003, RR 3.1
Southern blot analysis of C4A null alleles (C4A*QO)
Genomic DNA was extracted from peripheral blood white
cells [30] of nine patients and six controls who were found to
have C4A*QO genotypes. DNA samples were digested with the
restriction enzyme Hind III. DNA fragments were separated by
agarose gel electrophoresis and blotted into nitrocellulose mem-
branes as described by Southern [31]. The membrane-bound
DNA was hybridized with a 36P-radiolabeled 1.4 Kb long C4
probe (provided by David D. Chaplin, M.D.), which identified
the 5' end of C4A and C4B. The hybridized filter was washed
and subjected to autoradiography.
Statistics
Data were analyzed by the chi-square test or Fisher's exact
test when appropriate. All chi-square analyses were corrected
according to Yates' method. Further, P values were adjusted
with use of the Bonferroni correction for multiple comparisons
of HLA alleles. Therefore, P values for single HLA alleles were
multiplied by 71 (the total number of antigens tested). The
relative risk was determined by the method of Svejgaard et a!
[32].
Results
Class I and Class II HLA antigens
We did not find a significant association, after Bonferroni
correction, of single HLA-B8, B44, DR7, and B13 antigens with
steroid-sensitive nephrotic syndrome as has been described by
others (Table 1) [6—13]. Neither did our studies demonstrate the
Table 2. Frequencies of extended haplotypes in patients with steroid-
sensitive nephrotic syndrome





Extended haplotype Patients associated sians riska
Al ,B8,DR3,DRW52, 11/64(0.17) 4/80(0.05) 0.07 3.92
SCO 1
P <0.017 NS
B44,DR7,DRW53, 10/64(0.16) 3/80(0.04) 0.02 4.75
FC3 I
P 0.014 NS
a Patients vs. non-disease associated controls.
previously reported decreased frequency of DR2 [13]. None-
theless, uncorrected P values for DR2 and DR7 did reach
statistical significance for negative and positive association with
steroid sensitive patients, respectively. HLA-DQW2 allele phe-
notypic frequency was significantly increased when uncor-
rected, occurring in 23 of 32 steroid sensitive patients (72%),
compared to only 35% of the general population [22] (relative
risk: 3.1, Pc = 0.003). None of these antigens occurred with
unexpected frequency in the steroid resistant group.
Class III HLA antigens
A genotypic analysis of the complement genes C2, BF, C4A,
and C4B is also presented in Table 1. The common (C) variant
of C2 was not present in a significantly increased or decreased
frequency in steroid sensitive patients compared to controls.
None of the C4 variants occurred in unexpected frequencies. In
contrast to a previous report [15], C4A null was not significantly
increased. The distribution of Bf, a component of the alterna-
tive complement pathway C3 convertase, was also analyzed.
The two common Bf alleles, S and F, occurred in 67% and 33%
of the steroid sensitive patients, respectively, compared with
74% and 23% of the controls. The differences were not statis-
tically significant. We were also unable to confirm the previ-
ously suggested association [14] between factor B fast (F)
variant and idiopathic nephrotic syndrome. None of the Class
III antigens was increased in steroid resistant patients. Analysis
of the complotypes (linked complement genes) showed no
association with either group of nephrotic syndrome patients.
Extended haplotypes
Linkage disequilibrium between HLA alleles and complo-
types (extended haplotypes) was next examined (Table 2). The
frequency of the extended haplotype [HLA-A1, B8, DR3,
DRW52, SCO1] was found to be significantly increased (P =
0.017), occurring in 11 of the 64 steroid-sensitive associated
haplotypes (17%), in contrast with 4 of the 80 control haplo-
types (5%). The extended haplotype [HLA-B44, DR7, DRW53,
FC3 1] was found in 10 of 64 steroid-sensitive associated haplo-
types (16%), compared with 3 out of 80 of the control group
(3.8%). This frequency was also significantly greater (P =
0.014) in patients than in the controls. Five patients (15.6%) had
both extended haplotypes (Fig. 1). DQW2 occurred as a part of
the extended haplotypes in 5 of 11 patients with the B8, DR3
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A B A+B
Fig. 1. Extended haplotype frequencies in patients with steroid-sensi-
tive nephrotic syndrome (0) and normal controls (0). Complete
haplotypes are A = [HLA-Al, B8, DR3, DRW52, SCOI] and B =
[HLA-B44, DR7, DRW53, FC31].
extended haplotype and in 10 of the 10 patients with the B44,
DR7 extended haplotype. The six patients lacking DQW2 had
blank alleles instead. Neither haplotype was associated with
either specific glyoxalase variant. None of the steroid resistant
patients had either of these haplotypes; however, analysis of
this data was not feasible due to the small population sample
size.
Restriction fragment length polymorphism (RFLP) analysis of
C4A*QO
Fifteen individuals with the C4A*QO genotype were selected
for RFLP analysis. Results from each of the seven subjects,
four of whom were steroid sensitive patients and three controls,
who had the C4A*QO genotype and the [HLA-Al, B8, DR3,
DRWS2, SCO1] extended haplotype demonstrated that part of
the C4A gene was deleted (8.5 Kb Hind fragment). Thus, an 8.5
Kb remaining fragment was visible on their autoradiograms.
The eight subjects, consisting of four steroid sensitive patients,
one steroid resistant patient, and three controls who had the
C4A*QO genotype but did not have the Al, B8 extended
haplotype had normal Southern blot patterns (15 Kb and 25 Kb
Hind fragments) [33]. All patients with the C4A*QO genotype,
regardless of their steroid sensitivity or resistance, were het-
erozygous.
Clinical course
We evaluated whether the presence of either of the specific
extended haplotypes was associated with a variation in the
clinical course in the steroid sensitive patients. Patients with
one or both of the extended haplotypes had a higher average
relapse rate (3.3 per year) than those without the haplotypes
(2.5 per year). Although of questionable clinical significance,
this difference did reach statistical significance (P < 0.05).
Comparison of other clinical features, such as age at onset of
the disease, need for and response to cytotoxic therapy, and
histopathologic diagnosis, did not show any significant differ-
ences between the patients with one of the extended haplotypes
and those who had neither. No differences in clinical parame-
ters were seen comparing the B8 and B44 groups.
Discussion
We have demonstrated for the first time that HLA-DQW2
and two extended haplotypes, [HLA-Al, B8, DR3, DRW52,
SCO1] and [HLA-B44, DR7, DRW53, FC31], occur with a
significantly increased frequency in children with steroid-sensi-
tive nephrotic syndrome. We believe that the previously re-
ported increased frequencies of the single alleles, HLA-B44,
B8, DR3, DR7, BfF, and C4A*QO, are secondary to the
increased frequency of the extended haplotypes that bear the
corresponding alleles. The failure of others to identify an
increased frequency of these haplotypes [34] may relate to the
number of patients studied or the criteria used to select the
patients for study.
The relationship of the presence of the extended haplotypes
to the pathogenesis of nephrotic syndrome remains to be
determined, but may constitute a risk factor for the develop-
ment or severity of the disease. Steroid sensitive patients with
the B8 or 1344 extended haplotypes had significantly more
relapses of the nephrotic syndrome than the steroid sensitive
patients who did not have the extended haplotypes. In contrast,
none of the 10 steroid resistant patients had either of the
extended haplotypes. This may suggest that the presence of one
of the haplotypes contributes to susceptibility to steroid sensi-
tive disease. Interestingly, although 5 of 20 parents of steroid
resistant patients had one of the specific extended haplotypes,
none of their affected children inherited it. One must emphasize
caution in interpreting the data on steroid resistant patients,
however, since a small number of patients was studied.
Several clinical and laboratory findings in minimal change
nephrotic syndrome of childhood have implicated the a socia-
tion of abnormal immunity with the entity [20, 35—38]. It
remains unclear whether these play a role in the etiology of the
disease or are a consequence of some of the biochemical
changes that occur when a patient is in relapse [20]. The finding
that steroid-sensitive nephrotic syndrome is associated with
specific HLA extended haplotypes supports not only the con-
cept of an inherited predisposition to this disorder, but suggests
an abnormality of the immune response. A great deal of
information has been obtained about the function of the HLA
antigens in immune regulation [39]. The current concept of the
function of Class I and Class II antigens is that they act as a
guidance system for T cells. The T cell activation in response to
an antigen is produced by the interaction of the T cell receptor,
antigenic peptide, and Class I and Class II cell surface antigens.
Thus, an abnormality in any of the arms of this system could
predispose to disease. In addition, Porter [40] postulated that
susceptibility to diseases which have associated abnormalities
of complement could be determined by specific combinations of
complement alleles.
A possible relation of C4A null alleles in the pathogenesis of
steroid-sensitive nephrotic syndrome was considered because
of its strong linkage disequilibrium with the HLA antigens in the
B8 extended haplotype. Recently, Southern blot analysis of
several extended haplotypes containing C4A*QO has demon-
strated the presence of a deletion in the Class III region of the
HLA-B8, DR3 extended haplotype [41]. Null C4 alleles are
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systemic lupus erythematosus (SLE) [42]. Kemp et a! [43]
demonstrated an increased frequency of deletion of the C4A
gene in SLE, most commonly as part of the [HLA-A1, B8,
DR3, SCOI] extended haplotype. Our results were also consis-
tent with a deletion of C4A null alleles of patients and controls
only in the context of the B8 extended haplotype. Since the rest
of the patients with C4A*QO did not have the deletion, it is
unlikely that the partial C4A deficiency plays a direct role in the
pathogenesis of steroid-sensitive nephrotic syndrome. It is
possible that the deletion serves to maintain the B8 extended
haplotype by causing chromosomal misalignment, thereby sup-
pressing cross over events. The B8 extended haplotype in
linkage disequilibrium with GLO2 is also found associated with
type I diabetes mellitus [16, 17] and membranoproliferative
glomerulonephritis [181. The haplotype [HLA-B44, DR7, FC3 1]
has also been associated with gluten sensitive enteropathy [19].
The strong association of different diseases with the same
genetic marker (B8 extended haplotype) may indicate a com-
mon abnormality of immune responsiveness controlled by the
genes of the major histocompatibility complex region.
In conclusion, steroid-sensitive nephrotic syndrome appears
to be a multifactorial disorder with immunologic, genetic, and,
likely, environmental components. We conclude that the B8
and B44 extended haplotypes may provide genetic markers for
some forms of steroid-sensitive nephrotic syndrome. An abnor-
mal gene(s) leading to disease susceptibility may be located
within or near the major histocompatibility complex in the short
arm of chromosome 6. The strong association of DQW2 in
steroid sensitive patients, especially in those with the B44
extended haplotype, supports not only the concept that DQ is
also part of the extended haplotypes, but that the disease
susceptibility gene may be located in the Class II region of the
major histocompatibility complex. On the other hand, it is
possible that the extended haplotypes are mediators of the
defective immunoregulation of steroid-sensitive nephrotic syn-
drome, and that this is a primary factor in the disorder.
Furthermore, the observations indicate that the haplotypes can
be involved in the responsiveness of nephrotic patients to
corticosteroids. Better characterization of the HLA-extended
haplotypes by recombinant DNA techniques may be helpful in
further definition of disease markers.
The present study provides additional evidence for an inher-
ited basis for the development of steroid-sensitive nephrotic
syndrome, and suggests that this may involve an abnormality of
the immune system mediated by the major histocompatibility
complex. The exact connection between this observation and
the mechanism(s) responsible for the clinical features of steroid-
sensitive nephrotic syndrome remains to be delineated.
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